Neonatal hypoxic-ischemic encephalopathy (HIE) is a common disease among newborns, which is a leading cause of neonatal death and permanent neurological sequelae. Therapeutic hypothermia (TH) is the only method for the treatment of HIE that has been recognized effective clinically at home and abroad, but the efficacy is limited. Recent research suggests that the cord blood-derived mononuclear cells (CB-MNCs), which the refer to blood cells containing one nucleus in the cord blood, exert anti-oxidative, anti-inflammatory, anti-apoptotic effects and play a neuroprotective role in HIE. This review focuses on safety and efficacy, the route of administration, dose, timing and combination treatment of CB-MNCs in HIE.

新生儿缺氧缺血性脑病（HIE）是新生儿的常见病，是新生儿死亡和永久性神经后遗症的主要原因。低温治疗（TH）是国内外临床公认有效的治疗HIE的唯一方法，但疗效有限。最新研究表明，脐带血源性单核细胞（CB-MNCs）是指脐带血中含有一个核的血细胞，具有抗氧化、抗炎、抗凋亡作用，并在神经保护中发挥作用。嗨。本综述重点关注 CB-MNCs 在 HIE 中的安全性和有效性、给药途径、剂量、时机和联合治疗。